Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in Innsbruck, Austria
Blood vessels are the lifelines of our body. Diseases affecting their functionality remain one of the big unresolved global health problems. Especially diabetic patients suffer from a multitude of vascular complications that can cause blindness, non-healing wounds and kidney failure.
Angios strives to develop new treatments for these challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.
The vascular organoids allow us to model human microvascular complications in the dish and thereby find new pathways associated with disease progression. Additionally, the application of organoids for regenerative purposes holds great therapeutic potential.
Josef is currently the Director of the Life Sciences Institute at the University of British Columbia and was the founding Scientific Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences. He co-authored over 700
Josef is currently the Director of the Life Sciences Institute at the University of British Columbia and was the founding Scientific Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences. He co-authored over 700 publications and is an inventor on several patents. Josef received numerous awards, including the Wittgenstein Prize of the Austrian Federal Government, the Descartes Prize for Research, the Ernst Jung Prize for Medical Excellence, the Innovator Award of the US Department of Defense, and the Austrian Cross of Honor for Science and Art First Class.
Josef studied medicine at the University of Innsbruck in Austria and worked at the Ontario Cancer Institute as a post-doctoral fellow, before becoming Principal Investigator at the Amgen Institute and Associate Professor at the Departments of Immunology and Medical Biophysics in Toronto.
Dr. Gregor Wick
Gregor is an entrepreneur and consultant in the life sciences and biotech arena for 30 years. He worked with global management consultancies focusing on life sciences in Europe and the US. He is a founder of various start-ups in the health care space and is an advisor to venture capital and life sciences companies.
Gregor graduated with an M.A. and a PhD in Business administration and economics from the University of Economics in Vienna.
David Hoffmann, PhD
David holds a PhD in molecular biology from the University of Vienna and has experience in tumor angiogenesis and tumor glycosylation. He studied Molecular Biology at the University of Vienna and did his PhD in Josef Penninger’s laboratory at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences.